ANTISENSE PHARMA GmbH Begins Pivotal Phase III Clinical Trial with Trabedersen in Aggressive Brain Tumors
4/27/2009 9:10:51 AM
REGENSBURG, Germany--(BUSINESS WIRE)--The biopharmaceutical company Antisense Pharma GmbH has announced today that the first patients with recurrent or refractory anaplastic astrocytoma have been enrolled in the pivotal Phase III clinical trial SAPPHIRE. The SAPPHIRE study is a randomized, active-controlled, clinical trial designed to confirm the efficacy and safety of the investigational drug trabedersen (AP 12009), observed in the previous clinical studies. Trabedersen is being investigated as monotherapy compared to current standard therapy with temozolomide (alternatively BCNU). The results of the previous randomized, active-controlled Phase IIb study show that the novel, targeted therapy holds much promise.
comments powered by